Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Pain, AcutePain, ChronicChronic Post Operative Pain
Interventions
DIETARY_SUPPLEMENT

Butyrate and Taurine

This dose of butyrate is chosen to maximize any treatment effect in postoperative pain. Butyrate was reported to be safe at this dose for a prolonged period of 8 weeks. The dose of taurine is considered safe according to the European Food Safety Authority and was used in previous human perioperative trials. A human pharmacokinetic study showed that after taking 4g taurine (32 mmol) orally, plasma taurine levels reached a peak level of 86 mg/L (or 0.7 mmol/L) at 1.5 hours, exceeding the physiological plasma taurine level (0.01-0.1 mmol/L), which is needed to exert its pharmacological benefits.

OTHER

Placebo

indistinguishable placebo capsules will be administered orally after enrolment on the day before surgery, followed by daily administration for three months after surgery.

Trial Locations (1)

Unknown

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT07144033 - Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients | Biotech Hunter | Biotech Hunter